CoChat

Aromatase Inhibitors and Breast Cancer

Brodie, Angela M. H. · 1996 · Hormones and Cancer
Cited by 103

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Selective aromatase inhibitors cause regression of breast carcinomas by reducing estrogen production via inhibition of the enzyme aromatase (estrogen synthetase). A higher incidence of hormone-dependent breast cancer occurs in postmenopausal women than in younger women. Thus, total estrogen blockade is more likely to be achieved with systemic (pharmacologic) methods than by surgical removal of endocrine glands. At the present time, breast cancer patients with hormone-dependent disease usually receive the antiestrogen tamoxifen as first-line treatment. Although tamoxifen is effective initially, patients develop resistance to the drug, which results in disease progression. Aromatase inhibitors acting by a different mechanism from tamoxifen are effective in some of these patients. There is also the potential that aromatase inhibitors could be more effective as first-line treatment. Formestane, 4-hydroxyandrostenedione, the first approved aromatase inhibitor, is proving to be useful in postmenopausal breast cancer patients with advanced disease. Recently, anastrozole, a nonsteroidal agent, has been approved in the United States. Other very potent aromatase inhibitors are under development. Aromatase inhibitors as a new class of well-tolerated agents are now becoming available for improving the treatment of breast cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/978-1-4612-4266-6_12

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 103

Metadata

Authors
Brodie, A. M. H.
Venue
Hormones and Cancer
Published
1996
Volume
23
Issue
4 Suppl 9
Pages
357-376
ISSN
1868-8497 (ISSN-L)
OpenAlex
W4211219622
Cited by
103
References
5
FWCI
11.82
Type
book chapter
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aromatase Inhibitors and Breast Cancer. https://app.cochat.ai/papers/10.1007/978-1-4612-4266-6_12
The paper
Brodie, A. M. H. (1996). Aromatase Inhibitors and Breast Cancer. Hormones and Cancer. https://doi.org/10.1007/978-1-4612-4266-6_12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.